Effects of the Intragastric Balloon MedSil® on Weight Loss, Fat Tissue, Lipid Metabolism, and Hormones Involved in Energy Balance

The prevalence of obesity continues to increase worldwide. Because obesity is associated with a number health-related problems as well as a shortened life span, treating obesity is an important clinical concern. Although various treatments are currently available, many are not efficacious in the long term. Therefore, additional medical treatment options for morbidly obese individuals must be explored. In this study, we examined the effects of the intragastric balloon MedSilA (R) on anthropometric measures and hormones associated with lipid and energy metabolism. Twenty-two obese patients underwent insertion of the intragastric balloon MedSilA (R) following a clinical exam, body composition scan, and collection of blood samples. Six months following implantation of the balloon, additional anthropometric and serological measures were taken. Six months following insertion of the MedSilA (R) balloon, we observed significant decreases in body weight, body mass index, and fat mass. Compared with baseline levels, ghrelin serum levels were increased significantly, while leptin, FGF21, and glycated hemoglobin levels significantly decreased, 6 months after balloon insertion. The MedSilA (R) intragastric balloon is a safe and effective treatment for morbid obesity, with positive effects on anthropometric measures and lipid metabolism.